Analytical Data
-
Gene name
CHKa
- Application
-
Alternative Names
CHK-A; CHK; CKI; EK; Choline Kinase; Ethanolamine kinase
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O54804
-
Expression Region
Met1~Glu250
-
Molecular Weight
61kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHKa, or Choline Kinase Alpha, is a critical enzyme involved in the biosynthesis of phosphatidylcholine, a key component of cellular membranes. Its role extends beyond membrane formation, as it participates in various cellular processes, including signal transduction, cell growth, and differentiation. Dysregulation of CHKa has been implicated in several diseases, particularly cancer, where it is often overexpressed, leading to altered lipid metabolism and proliferation of cancer cells. The study of CHKa has gained traction in recent years due to its potential as a therapeutic target, as inhibiting its activity could disrupt tumor growth and improve responses to existing cancer treatments. Additionally, the production of recombinant CHKa proteins has facilitated the exploration of its structure-function relationship, enzymatic mechanisms, and interaction with other cellular proteins. By understanding the biochemical pathways involving CHKa, researchers aim to develop novel drugs that can selectively inhibit its activity, paving the way for new strategies in cancer therapy and providing insights into other metabolic disorders where aberrant choline metabolism plays a role.
